The EBMT Handbook : Hematopoietic Cell Transplantation and Cellular Therapies / edited by Anna Sureda, Selim Corbacioglu, Raffaella Greco, Nicolaus Kröger, Enric Carreras.

Format:

Book

Contributor:

Sureda, Anna, Editor.

Corbacioglu, Selim, Editor.

Greco, Raffaella, Editor.

Kröger, Nicolaus, Editor.

Carreras, Enric, Editor.

Series:

Medicine Series

Language:

English

Subjects (All):

Hematology.

Transplantation of organs, tissues, etc.

Internal medicine.

Children--Surgery.

Children.

Cancer--Treatment.

Cancer.

Transplantation.

Internal Medicine.

Pediatric Surgery.

Cancer Therapy.

Local Subjects:

Hematology.

Transplantation.

Internal Medicine.

Pediatric Surgery.

Cancer Therapy.

Physical Description:

1 online resource (XLII, 862 pages 62 illustrations, 47 illustrations in color)

Edition:

8th ed. 2024.

Place of Publication:

Cham : Springer International Publishing : Imprint: Springer, 2024.

Summary:

This Open Access 2nd edition of the EBMT handbook with its new format, addresses the latest developments and innovations in hematopoietic cell transplantation and cellular therapy. Consisting of 94 chapters, it has been written by 210 leading experts in the field. Discussing all types of hematopoietic cell transplantation, including selection of stem cell sources, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies and new infections (COVID-19). This book provides an unparalleled description of current practices to enhance readers’ knowledge and practice skills.

Contents:

Part I . Introduction

1. HCT: Historical Perspective

2. The EBMT: History, Present, and Future

3. Registries – a bridge between donor and recipient

4. The HCT Unit

5. JACIE Accreditation of HCT Programs

6. Statistical Methods in HCT and Cellular Therapies

Part II . Biological Aspects

7. Biological Properties Of Hematopoietic Stem Cells: Scientific Basis For Hematopoietic Cell Transplantation

8. Biological Properties of Cells Other Than HSCs

9. Histocompatibility

10. Clinical and biological concepts for mastering immune reconstitution after hematopoietic cell transplantation: towards practical guidelines and greater harmonization

Part III . Methodology and Clinical Aspects

11. Evaluation and Counseling of Candidates

12. Donor Selection for Adults and Pediatrics

13. Conditioning

14. Selection of stem cell source

15. Bone Marrow Harvesting for HCT

16. Mobilization and Collection of HSC

17. Mobilization and Collection of HSC in Children

18. Procurement and Management of Cord Blood Unit for allogeneic transplantation

19. Graft Manipulation

20. Processing, Cryopreserving and Controlling the Quality of HSC

21. Documentation of Engraftment and Chimerism After HCT

22. Short- and Long-Term Controls After HCT

Part IV . General Management of the Patient

23. Vascular Access

24. Transfusion Support

25. Nutritional Support

26. GVHD Prophylaxis

27. Infection Control and Isolation Procedures

28. General Management of the Patient: Specific Aspects of Infectious Disease Supportive Care in Children

29. Vaccinations

30. Psychological Morbidity and Care

31. Clinically Relevant Drug Interactions in HCT

32. The Roles of the HCT Nurse

33. Ethical Issues in HCT

34. Quality of Life Assessment After HCT for Pediatric and Adults

Part V. HCT Complications and Management

35. Neutropenic Fever

36. Bacterial Infections

37. Invasive fungal diseases

38. Viral Infections

39. Other Life-Threatening Infections

40. Bleeding and Thrombotic Complications

41. Graft Failure

42. Early complications of endothelial origin

43. Acute Graft-Versus-Host Disease

44. Chronic Graft-Versus-Host Disease

45. Post-transplant lymphoproliferative syndromes

46. Iron Overload

47. Secondary Neoplasia (Other than PTLPS)

Part VI . Specific Organ Complications

48. Ocular and Oral Complications

49. Hepatic complications

50. Gastrointestinal Complications

51. Haemorrhagic Cystitis and Renal Dysfunction

52. Noninfectious Pulmonary Complications

53. Neurological Complications

54. Skin, Hair and Musculoskeletal Complications

55. Cardiovascular Diseases and Metabolic Syndrome

56. Endocrine Disorders, Fertility and Sexual Health

Part VII . Prevention and Management of Relapse

57. Monitoring Measurable Residual Disease in ALL and AML

58. Prevention and Treatment of Relapse by Drugs

59. Delayed transfer of immune cells, or the art of donor lymphocyte infusion (DLI) 2.0

60. Cellular Therapy with Engineered T Cells, Efficacy and Side Effects: Gene Editing/Gene Therapy

61. Mechanisms of Immune Resistance

62. Regulatory Aspects Of Atmp Versus Minimally Manipulated Immune Cells

Part VIII . Specific Modalities of HCT and Management

63. At Home HCT

64. Role Of Umbilical Cord Blood Transplantation

65. Haploidentical HCT

66. Photopheresis in Adults and Pediatrics

67. Overweight and obese patients

68. HCT in Elderly Patients

69. Feasibility and Experiences of HCT in Resource-constrained Settings

Part IX . Indications and Results

70. AML in adults

71. Acute Myeloid Leukemia in Children

72. Acute Lymphoblastic Leukemia in Adults

73. Acute Lymphoblastic Leukemia in Children and Adolescents

74. Myelodysplastic Neoplasms/Syndromes (MDS)

75. Allogeneic hematopoietic cell transplantation in pediatric MDS including refractory cytopenia of childhood and in juvenile myelomonocytic leukemia

76. Myelodysplastic/Myeloproliferative Neoplasms

77. Myeloproliferative Neoplasms

78. Acquired bone marrow failure: Severe Aplastic Anemia and Paroxysmal nocturnal hemoglobinuria

79. Fanconi Anemia and Other Hereditary Bone Marrow Failure Syndromes

80. Hemoglobinopathies (Sickle Cell Disease and Thalassemia)

81. Multiple Myeloma

82. Systemic Light Chain Amyloidosis

83. Poems Syndrome And Disease Produced By Other Monoclonal IGS

84. Indolent Lymphoma

85. CHRONIC LYMPHOCYTIC LEUKEMIA

86. Large B-Cell Lymphoma

87. Mantle Cell Lymphoma

88. Other B- and T-Aggressive Lymphomas & Lymphomas Associated with HIV

89. Classical Hodgkin’s Lymphoma

90. Inborn errors of immunity

91. Inborn Errors of Metabolism and Osteopetrosis

92. Autoimmune Disease

93. CART cells & other cell therapies (ie MSC, Tregs) in autoimmune diseases

94. Solid Tumours.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9783031440809

3031440803

OCLC:

1430658033